Selank and Semax: what the evidence says and what it doesn't

Selank y Semax: qué dice la evidencia y qué no

They show up in the same ads. A small vial, a name that sounds like a lab code, and a large promise: calm without sedation, focus without caffeine, a brain that finally cooperates.

They are called Selank and Semax. They are peptides — short chains of amino acids — and online they are sold as if they were supplements. They are not.

This article is not going to tell you they are a miracle or a poison. It is going to tell you exactly what has been studied, where, in whom, and what the FDA said when it had to review them. Then you decide, with a physician.

Educational content. Not medical advice. Results vary.

What these two peptides actually are

A peptide is a short chain of amino acids. Your body makes hundreds of them every day and uses them as messengers: open this door, close that one, signal that it is time to sleep or time to eat.

Selank has seven amino acids. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, and it did not come out of nowhere: it is a synthetic version of tuftsin, a natural fragment your immune system already produces.

Semax also has seven. The first four come from ACTH, a hormone made by your pituitary gland. A three-amino-acid tail — Pro-Gly-Pro — was added to those four for a practical reason.

Natural peptides are destroyed very fast in the bloodstream. Minutes, sometimes less. That added tail makes the molecule last longer before enzymes cut it apart. It is a chemistry trick, and it is the same trick used in approved medicines.

That said: an elegant idea is not the same as an effect in you. That is a different question, and it takes up the rest of this article.

Where they come from: Russia, not the United States

Both were born in the same place: the Institute of Molecular Genetics of the Russian Academy of Sciences, in Moscow. Open the papers and you will see the same surname — Myasoedov — on nearly all of them, from the 1990s until today.

That is not an accusation. It is context, and it changes how the results should be read.

Most of the clinical trials of Selank were published in Russian journals, in Russian, with Russian patients, compared against drugs that are not even sold in the United States. Phenazepam and medazepam, which appear as comparators, do not exist at your corner pharmacy.

And something that matters a great deal in medicine is missing: independent replication. That is, another group, in another country, unconnected to whoever invented the molecule, repeating the study and getting the same result.

When that happens, confidence rises a lot. When it does not — and with these two peptides, largely, it has not — the result is not discarded, but it stays in a more fragile category: promising, not confirmed.

Selank: the anxiolytic that isn't a benzodiazepine

To understand what Selank does you first have to understand GABA.

GABA is the main brake of your nervous system. When it is activated, neurons slow down. Less noisy anxiety, less muscle tension, easier sleep.

Benzodiazepines — alprazolam, clonazepam — work there. They press the brake harder. They work, and they work fast. The price is well known: drowsiness, memory problems, tolerance and dependence if use drags on.

A 2018 paper from the same Russian institute described what Selank does in brain cell membranes: it behaves as a positive allosteric modulator of the GABA receptor. Translated: it does not press the brake itself. It appears to make the brake respond better when your own body's GABA arrives.

Something curious showed up in that same work. When Selank was put together with diazepam or olanzapine, the effect did not simply add up — it was different. Selank was able to block part of the modulatory activity of those drugs. The authors concluded that the binding sites are probably not the same, though they may partly overlap.

The uncomfortable detail almost nobody quotes

In 2017, another study from the same group measured 84 GABA-system genes in human neuroblastoma cells. The result with Selank alone? No change. None.

The effect appeared only when Selank was combined with GABA — and what it did there was very nearly cancel out the changes GABA produced on its own.

It is an honest data point and worth holding onto: even inside the group that developed the molecule, the mechanism is not settled.

What was seen in patients

There are trials in people, and they are small.

One from 2008 compared Selank against medazepam in 62 patients with generalized anxiety disorder and neurasthenia. The anxiolytic effect was similar between the two, but Selank added something the benzodiazepine did not: an anti-asthenic, mildly stimulating component — less fatigue, not more.

Another, from 2015, with 70 patients in total, tested a different idea: not replacing the benzodiazepine, but accompanying it. Forty patients received phenazepam plus Selank and thirty received phenazepam alone.

The combined group reached the effect earlier on the Hamilton scale. And — this is the interesting part — reported fewer of the tranquilizer's unwanted effects: less attention and memory impairment, less sedation, less emotional flattening, both during treatment and after withdrawal.

Seventy people. For comparison: a trial the FDA would accept to approve an anxiolytic usually has hundreds or thousands of participants, across several countries, with assessors who do not know who received what.

How U.S. pharmacology sees it

In 2021, a review in the Journal of Clinical Pharmacology surveyed sedatives that act on GABA. It put Selank in the same paragraph as phenibut and wrote a sentence worth reading in full: these are poorly studied Russian drugs with GABAergic mechanisms that are sold to U.S. consumers as dietary supplements — something the authors called inexplicable.

That review also noted that this family of substances, used at high doses or alongside other depressants, is associated with respiratory depression and withdrawal syndromes. It does not say Selank does that. It says Selank sits in a family where that happens, and that nobody has properly measured where he stands.

Semax: a stroke drug that became a "nootropic"

There is a leap here that almost nobody explains.

In Russia, Semax is registered and used mainly for ischemic stroke — the kind caused by a blocked blood supply — and it is given through the nose. That is its real use. It is not a capsule for studying better.

The evidence you can read in English is, almost all of it, mechanism work in rats.

In 2014, a genome-wide analysis in the brain cortex of rats with focal ischemia found that Semax mostly changed immune system genes. At 24 hours, more than half of all the genes affected were immune genes — immunoglobulins and chemokines, chiefly. It also moved vascular genes, tied to the formation of new blood vessels.

In 2021, the same group confirmed it at the protein level: active CREB up in the damaged area, and MMP-9, c-Fos and active JNK down. In plain language: less inflammation and less cell death, more repair signal.

And in 2025, work published in the British Journal of Pharmacology tested Semax in female mice with spinal cord injury. It improved functional recovery, and the authors traced the effect to the mu opioid receptor and a protein called USP18.

All of that is interesting. None of it is a healthy person trying to concentrate.

The copper chapter

There is a separate line of research, and it is test tube chemistry.

Semax binds copper very tightly. In 2022 and again in 2025, Italian researchers showed it can strip copper away from the amyloid beta protein — the Alzheimer's one — reduce the free radicals that pairing generates, and protect cells in culture.

It is elegant. And the distance between that and a person with Alzheimer's is enormous. If this feels familiar, it is because it is the same "copper peptide" logic as GHK-Cu, where we wrote the same thing: the laboratory is running far ahead of the clinic.

The one study in healthy people you can read in English

There is exactly one, and it deserves its own section precisely because it is the one most often misquoted.

In 2020 a study was published with 52 healthy participants. They underwent resting-state functional MRI three times: before the injection, 5 minutes after, and 20 minutes after. Some received Semax, some Selank, some placebo.

Differences were found in the connectivity between the right amygdala — a key region for regulating fear and anxiety — and a region of the right temporal lobe. The authors described both general and peptide-specific effects.

Now read this carefully, because it is the part the ads skip.

The study measured how brain regions communicate at rest. It did not measure whether anyone felt less anxious. It did not measure whether anyone performed better on a task. It did not measure whether the effect lasts longer than twenty minutes.

A signal on a scan is a hint that something is happening. It is not a benefit. Between those two things sit years of research that, in this case, do not yet exist.

What the FDA says, in its own words

In the United States, a compounding pharmacy may prepare a customized medicine under a section of the law called 503A. But it cannot use just any ingredient: the substance has to meet an official monograph, or be a component of an already-approved drug, or appear on a specific FDA list.

While it evaluates candidates, the FDA sorts them. Category 2 is the bad one: substances nominated with enough information to be evaluated, but for which the agency identified significant safety risks.

Selank and Semax were there. And the reason the agency gives is not what people imagine.

The main risk the FDA names is immunogenicity: the possibility that an injected or inhaled peptide, if its molecules clump together or if it carries impurities from manufacturing, provokes your immune system to react against it.

But the most important sentence is the other one. On Selank, the FDA writes that it lacks important information regarding any safety issues raised by selank acetate administered to humans. On Semax, that it has no or only limited safety information for the proposed routes, and therefore lacks sufficient information to know whether the drug would cause harm if administered to humans.

That is worth reading twice. It does not say "proven harmful." It says nobody knows.

Those are not the same thing, and confusing them cuts both ways: it does not justify dramatic prohibition, and it does not justify selling them as if they were clean.

April and July 2026: what changed and what didn't

Two things happened this year that sellers quote by halves.

April 22, 2026. The FDA moved a group of peptides — Selank and Semax among them — into a new table titled "bulk drug substances nominated but withdrawn." The reason was administrative: the parties who had nominated them withdrew the nomination.

What did not change: the FDA's risk paragraphs are still published, word for word, on that same page. Coming off a list because the paperwork was pulled is not the same as receiving an approval.

July 23-24, 2026. The Pharmacy Compounding Advisory Committee reviewed seven peptides. It voted 8 to 5 in favor of Semax for the 503A list, 7 to 4 in favor of epitalon, and against DSIP by 6 to 7. Selank was not on that docket.

Here is the nuance that decides everything: an advisory committee advises. The FDA is not obligated to follow it, and adding a substance to the 503A list requires a formal rulemaking process with a public comment period. That takes time.

Put plainly: the day of that vote, nothing changed about what you can legally buy today.

The risk that isn't pharmacological

There is a risk science barely discusses because it is not scientific. It is logistical.

Most of what is sold online is labeled "for research use only" or "not for human consumption." That label is not a decorative technicality: it is what allows the product to be sold without meeting the rules that apply to a medicine.

In practice that means: no verifiable certificate of analysis, no FDA-registered manufacturer, no real dose control, nobody answerable if the vial contains something else.

And look at the irony. The FDA's specific concern is molecular aggregation and peptide-related impurities. That is exactly what uncontrolled manufacturing produces. The risk the agency describes is not theoretical in a serious pharmaceutical facility — it is far more real in a vial bought online.

The most common format sold is a nasal spray, because it avoids the needle and feels harmless. The nose is not a barrier: it is a direct absorption route, which is precisely why the FDA names it explicitly among the routes that concern it.

What this evidence does NOT say

• It does not say Selank works in a U.S. population. The trials were run in Russia, with diagnostic criteria and comparator drugs that are not used here.
• It does not say Semax improves memory or focus in healthy people. Its clinical evidence is stroke evidence. A brain recovering from a stroke and a brain that wants to perform better at work are not the same problem.
• It does not say they are dangerous. The FDA did not claim that. It stated there is not enough information to know — a different and more uncomfortable category.
• It does not say a nasal spray equals an injection. Each route has its own absorption and safety profile, and the FDA treats them separately.
• It says nothing about long-term use. Human studies last weeks. Nobody has followed someone using this for years.
• It says nothing about combinations. There is no serious data on mixing them with antidepressants, anxiolytics, stimulants or alcohol.
• It does not say animal research translates. A 2026 review in JAAOS Global Research & Reviews, surveying therapeutic peptides including Selank and Semax, sums it up in one line: preclinical studies are promising, but there is a current lack of clinical trials.

Where you need to slow down

Nobody has to ask permission to be curious. But there are situations where this is not a decision you make alone, and where a physician has to weigh in first, not afterwards:

• If you are pregnant or breastfeeding. There is no nuance here: there is no data, none, which is why the answer is to wait.
• If you have an untreated anxiety or mood disorder. It is not that you cannot explore other things — it is that starting here, alone, can delay treatment that does have evidence behind it. Diagnosis first, then the conversation.
• If you take benzodiazepines or other central nervous system depressants. The 2018 work showed interactions that do not add up predictably, and there are no safety studies of that combination.
• If you have an autoimmune condition. The risk the FDA names is immunological. In an already dysregulated immune system, that risk is not theoretical.
• If you are under 18. There is no data, and a developing brain is not a place to experiment.
• If you want focus and haven't checked the basics. Sleep, thyroid, iron, B12, glucose, sustained stress. Most of the "brain fog" that reaches a clinic has a measurable, boring cause. Checking that first costs you nothing: it tells you whether the problem was something else.

Frequently asked questions

Are Selank and Semax legal in the United States?

Neither is FDA-approved for any indication, and neither is on the 503A list that lets a compounding pharmacy prepare them. What is sold online relies on a "research use" label, which does not authorize human consumption.

Didn't the July 2026 vote approve them?

No. It was an advisory committee recommendation in favor of Semax, 8 votes to 5. The FDA is not obligated to follow it, and the formal change requires a rulemaking process that has not concluded. Selank was not even on that docket.

If they're registered in Russia, isn't that enough?

Each agency applies its own evidence standard. Approval in one country does not mean acceptance in another, and in this case most trials are small, from a single research group, and without independent replication outside that country.

Doesn't the MRI study prove they work?

It proves that differences in resting brain connectivity appear minutes after a dose, in 52 healthy people. It did not measure anxiety, or performance, or duration. A signal on a scan is not a clinical benefit.

And if I'm still interested?

Then the conversation belongs with a physician, not with a salesperson. Write to us and a licensed physician reviews your full case — what you are after, your history, what you have already tried — and tells you plainly what is possible, what is not possible yet, and what better-evidenced options exist for what you are actually dealing with. Nobody is going to tell you not to ask.

If you are still interested: how we handle it

We could have written this article a different way. There is a version that starts the same and ends by selling you a vial. We did not write it, and not because we are better than anyone: because the day we sell you something that does not hold up, you stop believing us forever.

But we are not going to do the opposite either, which is just as easy: tell you not to ask. Your curiosity is not the problem. The problem is buying blind from a site that does not answer the phone.

So if you have read all of this and you are still interested, the conversation does not end here — it moves to where it should have been from the start: a licensed physician looking at your full case. Write to us and that is what happens. They will tell you plainly what is possible today, what is not possible yet, and what better-evidenced options exist for what you are dealing with.

Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary.

We also offer clinically supervised hormone health and weight management programs, and GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149 a month, by telemedicine, in Spanish and English. That is there if it is useful to you — and if it is not, that is fine too.

Eligibility is determined by medical evaluation. Individual results vary and are not guaranteed.

Sources

Articles located through PubMed. Regulatory documents taken directly from the FDA.

• Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. 10.2174/0929866525666180925144642
• Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. 10.3389/fphar.2017.00089
• Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. 10.17116/jnevro20151156133-40
• Doyno CR, White CM. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol. 2021;61 Suppl 2:S114-S128. 10.1002/jcph.1922
• Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. 10.1134/S001249662001007X
• Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia. BMC Genomics. 2014;15:228. 10.1186/1471-2164-15-228
• Sudarkina OY, Filippenkov IB, Stavchansky VV, et al. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4-7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. Int J Mol Sci. 2021;22(12):6179. 10.3390/ijms22126179
• Liu R, Chen Y, Huang H, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025;182(22):5489-5516. 10.1111/bph.70122
• Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. ACS Chem Neurosci. 2022;13(4):486-496. 10.1021/acschemneuro.1c00707
• Tomasello MF, Di Rosa MC, Naletova I, et al. Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of Aβ by Metal Ion Stripping and Redox Silencing. Bioinorg Chem Appl. 2025;2025:4226220. 10.1155/bca/4226220
• Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). 10.5435/JAAOSGlobal-D-25-00236
• FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2; content current as of 04/22/2026). fda.gov
• FDA — Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 05/14/2026). fda.gov
• FDA — Meeting of the Pharmacy Compounding Advisory Committee, July 23-24, 2026. fda.gov

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medications. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform. Eligibility is determined by a licensed provider. Selank and Semax are not FDA-approved for any indication and, as of publication, do not appear on the 503A list of substances a compounding pharmacy may use; they are discussed here for informational and educational purposes only, and not as a recommendation of use. Any treatment decision belongs to a licensed physician who has evaluated your case. Individual results vary and are not guaranteed.